Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651932 · ClinicalTrials.gov registry record · Phase 1
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Myeloma, sponsored by K36 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT05651932: Recruiting Phase 1 study of Multiple Myeloma and Myeloma, sponsored by K36 Therapeutics.
NCT05651932 is a Phase 1 study of Multiple Myeloma and Myeloma that is actively recruiting participants, run by K36 Therapeutics. The registered enrollment target is 125 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05651932, a Phase 1 study of Multiple Myeloma and Myeloma, is actively recruiting participants, sponsored by K36 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Primary Outcome
Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory test results
Conditions Studied
Interventions
- DRUG Cohort A1 & A2: KTX-1001
- DRUG Cohort B1 & B2: KTX-1001+Mezigdomide
- DRUG Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- DRUG Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Study Locations (20)
Other
- Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu - Nantes
- Centre Hospitalier Universitaire de Poitiers (CHU de Poitiers) - Poitiers
- Institut Universitaire du Cancer de Toulouse - Oncopole - Toulouse
- Hospital ClÃ-nic de Barcelona - Barcelona
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- Atrium Health, Levine Cancer Institute - Charlotte
- Duke University Hospital - Durham
California
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic - San Francisco
Florida
- Mayo Clinic Hospital - Florida - Jacksonville
Georgia
- The Winship Cancer Institute of Emory University - Atlanta
Minnesota
- Mayo Clinic - Transplant Center - Rochester - Rochester
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
What NCT05651932 shows while recruiting
NCT05651932 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cohort A1 & A2: KTX-1001 is the first listed.
NCT05651932 names 20 study sites across 15 states, led by Other, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05651932 about?
NCT05651932 is a clinical study titled "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma". A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
What is the current status of trial NCT05651932?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2023-02-22. Estimated completion is 2028-06-30.
What conditions does trial NCT05651932 study?
This clinical trial studies the following conditions: Multiple Myeloma, Myeloma, Myeloma Multiple.
What interventions are being tested in trial NCT05651932?
The interventions under investigation include: Cohort A1 & A2: KTX-1001 (DRUG), Cohort B1 & B2: KTX-1001+Mezigdomide (DRUG), Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) (DRUG), Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid) (DRUG).
Who is sponsoring clinical trial NCT05651932?
This trial is sponsored by K36 Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05651932 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05651932's enrollment target sits among peer trials
125 148th of 438 higher than 291 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI